MedTrace Logo

The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

NCT01706939 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2026-04-09

Study results available
· View outcomes & findings →

Summary

This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups. The study hypothesis is that LRC and PFS at 3 years for reduced dose CRT are non-inferior to standard dose CRT.

Conditions

  • Squamous Cell Carcinomas

Interventions

RADIATION

Reduced Dose Radiation

Reduced Dose Radiation (5600 cGy) dose radiotherapy

RADIATION

Standard Dose Radiation

Standard Dose Radiation (7000 cGy) dose radiotherapy

DRUG

Carboplatin

Day 1, every 7 days ( + 2 days)

Sponsors & Collaborators

Principal Investigators

  • Krzysztof Misiukiewicz, M.D. · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-01
Primary Completion
2020-04-01
Completion
2035-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01706939 on ClinicalTrials.gov